SR9009 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
The number of horses killed was unprecedented in modern warfare. The wastage was particularly heavy among British forces for several reasons: overloading of horses with unnecessary equipment and saddlery, failure to rest and acclimatise horses after long sea voyages and, poor management by inexperienced mounted troops and distant control by unsympathetic staffs. The average life expectancy of a British horse, from the time of its arrival in Port Elizabeth, was around six weeks. Most horses and mules brought to South Africa came from the US. In total, 109,878 horses and 81,524 mules were shipped from New Orleans to South Africa in 166 voyages from October 1899 to June 1902. The cost of these animals and their transport was an average of US$597,978 per month. A significant number of horses and mules died during the transit; for example, during the SS Manchester City's 36-day passage, 187 of her 2,090 mules died. Horses were slaughtered for their meat when needed. During the sieges of Kimberley and Ladysmith, horses were consumed as food once regular sources were depleted. The besieged British forces in Ladysmith also produced chevril, a Bovril-like paste, by boiling down the horse meat to a jelly paste and serving it like beef tea. The Horse Memorial in Port Elizabeth is a tribute to the 300,000 horses that died during the conflict.
== Disorder and disease == Intrinsically unstructured proteins have been implicated in a number of diseases. Aggregation of misfolded proteins is the cause of many synucleinopathies and toxicity as those proteins start binding to each other randomly and can lead to cancer or cardiovascular diseases. Thereby, misfolding can happen spontaneously because millions of copies of proteins are made during the lifetime of an organism. The aggregation of the intrinsically unstructured protein α-synuclein is thought to be responsible. The structural flexibility of this protein together with its susceptibility to modification in the cell leads to misfolding and aggregation. Genetics, oxidative and nitrative stress as well as mitochondrial impairment impact the structural flexibility of the unstructured α-synuclein protein and associated disease mechanisms. Many key tumour suppressors have large intrinsically unstructured regions, for example p53 and BRCA1. These regions of the proteins are responsible for mediating many of their interactions. Taking the cell's native defense mechanisms as a model drugs can be developed, trying to block the place of noxious substrates and inhibiting them, and thus counteracting the disease.
== Early life and education == Jorgenson was born on September 9, 1952, in Kenosha, Wisconsin. He received a Bachelor of Science degree in chemistry from Northern Illinois University in 1974 and a PhD in chemistry from Indiana University in 1979.
2025 Steven Henikoff, for his transformative research on genome organization and gene expression. 2024 Winrich Freiwald, Nancy Kanwisher, Margaret Livingstone, Doris Tsao for discovering how and where in the brain face recognition occurs. 2023 Wolfgang Baumeister, for his pioneering work in the development of cryo-electron tomography and his insights into the structures and functions of the protein quality control machinery 2022 Christine Holt and Erin Schuman, for their pioneering work that shed light on the role of local protein synthesis in neuronal development and function. 2021 Robert H. Singer, for his key role in revealing the dynamics of gene expression using high-resolution imaging. 2020 Katalin Karikó and Drew Weissman, for their pioneering work in the modification of nucleic acids to develop RNA therapeutics and vaccines. 2019 David Julius and Ardem Patapoutian, for their remarkable contributions to our understanding of the sensations of temperature, pain and touch. 2018 Stephen C.
Sources: en.wikipedia.org
== Research == Luvesilocin is under development for the treatment of postpartum depression (PPD), treatment-resistant depression, and other psychiatric disorders. As of September 2025, it has reached phase 2 clinical trials for these indications. A phase 3 trial is planned for 2026. The drug is being developed by Reunion Neuroscience (formerly known as Field Trip Health).
=== Speciality style ciders === Speciality style ciders are open to a lot more manipulation than modern or heritage style ciders. There is no restriction to apple varieties used and the list of speciality styles continues to expand. Listed on the USACM Cider Style Guide, speciality styles include: fruit, hopped, spiced, wood-aged, sour, and iced ciders. Fruit ciders have other fruit or juices added before or after fermentation, such as cherries, blueberries and cranberries. Hopped cider is fermented with added hops, common hop varieties being Cascade, Citra, Galaxy, and Mosaic. Spiced ciders have various spices added to the cider before, during, or after fermentation. Spices like cinnamon and ginger are popular to use in production. Wood-aged ciders are ciders that are either fermented or aged in various types of wood barrels, to aid in extraction of woody, earthy flavours. Sour ciders are high acid ciders that are produced with non-standard, non-Saccharomyces yeast and bacteria, which enhance acetic and lactic acid production, to reach a sour profile. Ice ciders can be made by using pre-pressed frozen juice or frozen whole apples. Whole apples either come frozen from the orchard, dependent on harvest date, or are stored in a freezer prior to pressing. When the pre-pressed juice or whole apples freeze, sugars are concentrated and mostly separated from the water. Whole apples are then pressed to extract the concentrated juice. For the pre-pressed juice the concentrated solution is drawn off while thawing occurs.
For instance, the Lois lab at Caltech is using engineered artificial ligands and receptors on neurons to trace information flow in the brain. They are specifically using ligand-induced intramembrane proteolysis to unravel the wiring of the brain in Drosophila and other models. When the artificial ligand on one neuron binds to the receptor on another, GFP expression is activated in the acceptor neuron demonstrating the usefulness of ligand binding assays in neuroscience and biology.
In reaction that is the reverse of its biosynthesis, asparagine is hydrolyzed to aspartate by asparaginase. Aspartate then undergoes transamination to form glutamate and oxaloacetate from alpha-ketoglutarate. Oxaloacetate, which enters the citric acid cycle (Krebs cycle).
Following Geoffrey Howe's resignation speech in November 1990, Heseltine challenged Thatcher for the party leadership, polling well enough to deny her an outright victory on the first ballot. Following Thatcher's subsequent resignation, Heseltine lost to Major on the second ballot, but returned to the Cabinet in his former post of Environment Secretary when Major became prime minister. As a key ally of Major, Heseltine was appointed President of the Board of Trade and Secretary of State for Trade and Industry following the 1992 general election. He supported Major when his leadership was challenged in 1995, and was promoted to Deputy Prime Minister and First Secretary of State. He declined to seek the leadership of the party following Major's 1997 election defeat, and served in Major's shadow cabinet as Deputy Leader of the Opposition, Shadow Chancellor of the Duchy of Lancaster and Shadow Secretary of State for Trade and Industry while the leadership election to succeed him was taking place. Heseltine was created a life peer in 2001 and has remained a vocal advocate of modernisation within the party. He has continued to make political interventions, criticising Brexit and Boris Johnson following the 2016 Brexit referendum result. In 2019, Heseltine had the whip suspended after saying he would vote for the Liberal Democrats, rather than the Conservatives, at the 2019 European Parliament election. Heseltine had the whip restored in July 2024.
Sources: en.wikipedia.org
Hyperphosphorylation of the tau protein (tau inclusions, pTau) can result in the self-assembly of tangles of paired helical filaments and straight filaments, which are involved in the pathogenesis of Alzheimer's disease, frontotemporal dementia and other tauopathies. All of the six tau isoforms are present in an often hyperphosphorylated state in paired helical filaments in the Alzheimer's disease brain. In other neurodegenerative diseases, the deposition of aggregates enriched in certain tau isoforms has been reported. When misfolded, this otherwise very soluble protein can form extremely insoluble aggregates that contribute to a number of neurodegenerative diseases. Tau protein has a direct effect on the breakdown of a living cell caused by tangles that form and block nerve synapses. Gender-specific tau gene expression across different regions of the human brain has recently been implicated in gender differences in the manifestations and risk for tauopathies. Some aspects of how the disease functions also suggest that it has some similarities to prion proteins.
On July 13, 2024, Trump survived an assassination attempt while addressing a campaign rally near Butler, Pennsylvania. Trump was shot and wounded on his right ear by 20-year-old Thomas Crooks, who fired eight rounds with an AR-15–style rifle from the roof of a building approximately 400 feet (120 metres) from the stage; the shots killed one audience member and critically injured two others. Seconds later, Crooks was shot and killed by the U.S. Secret Service's counter-sniper team. On September 11, 2024, a bipartisan Senate report identified technical issues and other preventable mistakes by the Secret Service during the event. On September 15, 2024, Trump survived a second assassination attempt at Trump International Golf Club in West Palm Beach, Florida. The perpetrator, 58-year-old Ryan Wesley Routh, took position in nearby shrubbery holding an SKS-style rifle just outside the fence of the golf course. After hiding there for nearly 12 hours, Routh pointed his weapon through the fence line, approximately 400 yards (370 m) away from Trump. A Secret Service agent noticed this and fired four rounds towards Routh, who fled the scene and was later captured in Martin County. No injuries were reported. Routh was later indicted on five federal charges and three state charges, all of which Routh pleaded not guilty to. His trial began on September 8, 2025. Two weeks later on September 23, Routh was found guilty on all federal counts, where he then grabbed a pen and attempted to stab himself in the neck, before being tackled by U.S. marshals.
== Directors == Lenton Parr, 1972–1984 (Victorian College of the Arts proclaimed 30 November 1972) Lionel Lawrence, 1985–1988 Alwynne Mackie, 1989–1995 Andrea Hull, 1995–2009 Su Baker, 2010–2017 Jon Cattapan, 2017–2020 Barbara Bolt, 2020–2021 Emma Redding, 2022–present
== In viruses == Glutaredoxin has been sequenced in a variety of viruses. On the basis of extensive sequence similarity, it has been proposed that Vaccinia virus protein O2L is, it seems, a glutaredoxin. Bacteriophage T4 thioredoxin seems to be evolution-related. In position 5 of the pattern T4, thioredoxin has Val instead of Pro.
The analog of the poly-Pro II helix in poly-glycine is called the poly-Gly II helix. Some proteins, such as the antifreeze protein of Hypogastrura harveyi consist of bundles of glycine-rich polyglycine II helices. This remarkable protein, whose 3D structure is known, has unique NMR spectra and is stabilized by dimerization and 28 Cα-H··O=C hydrogen bonds. The PPII helix is not common in transmembrane proteins, and this secondary structure does not traverse lipid membranes in natural conditions. In 2018, a group of researchers from Germany experimentally observed the first transmembrane PPII helix formed by specifically designed artificial peptides.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.